Original studiesBone mineral density in adolescent females using depot medroxyprogesterone acetate☆
Introduction
Bone mineral density (BMD) in females accrues steadily throughout childhood, then rises exponentially during puberty, especially during the ages of 11 through 14, and plateaus with sexual maturity by age 19.1 Up to 90% of the total adult bone content is acquired at the end of the teenage years.2 Therefore, critical changes in bone mass occurring during adolescence may have a profound effect given the peak bone accumulation at this stage of life. Depot medroxyprogesterone acetate (DMPA) is a popular contraceptive method among adolescents because of its effectiveness and dosing schedule. Multiple reports in adults have shown a definitive decrease in bone mineral density in those who use DMPA, with a suggested recovery after discontinuation.3., 4., 5. Evidence in the adolescent population is limited to one report by Cromer et al, who noted decrease in BMD of 3.1% at 2 years in a small number of adolescent patients (n = 8) compared to pill users, levonorgestrel insert users, and normal menstruating controls.6
The objective of this study was to prospectively examine BMD on a semi-annual basis among control subjects and adolescent females receiving DMPA injection or oral contraceptives.
Section snippets
Materials and methods
Approval was received from the Institutional Review Board at the University of Louisville School of Medicine, and signed informed consent was obtained from the patient and from her legal guardian when appropriate. Adolescent females between the ages of 11 and 21 years who presented to our teenage pregnancy prevention intervention clinic who were new users of DMPA injection or the combination oral contraceptive pill were prospectively evaluated. Controls were recruited from those patients that
Results
Data from 148 consecutively recruited patients were included at baseline in the study for analysis. The overall population characteristics at baseline are illustrated on Table 1 and show no difference in mean age, age distribution, BMD, body mass index, smoking or exercise between groups. A greater percentage of African American girls were noted in the DMPA group compared to controls. Patients' group distribution at different followup intervals is presented on Table 2.
Table 3 and Fig. 1
Discussion
Although most studies in adults agree that DMPA negatively affects BMD, Bohamondes et al showed no difference in 50 premenopausal women who used DMPA and those who didn't with a mean age of 31 years old.7 Scholes et al also showed that although patients using DMPA had a decrease on BMD at all ages (18–39 years old). After discontinuation of the drug, patients BMD values returned to normal and noted no difference with non-hormone users.8 This trend was also more marked for recovery in the
Conclusion
The results of our study reject the null hypothesis; in fact there seems to be a relationship between the use of DMPA and a decrease in BMD compared to normal menstruating controls that seems to persist up to 24 months. Further longitudinal longer-term studies may be required to evaluate the impact on adult BMD.
Acknowledgements
We thank Gil Haugh, MS, from the Outcomes Research Institute, University of Louisville, for his help with the statistical analysis. This paper was presented at the North American Society for Pediatric and Adolescent Gynecology 17th Annual Clinical Meeting in May 2003 as the first prize original research award. Funding was provided by the Alliant Community Trust Foundation.
References (18)
- et al.
Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health
Obstet Gynecol
(2000) - et al.
A prospective controlled study of hormonal contraception on bone mineral density
Obstet Gynecol
(2001) - et al.
A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), Levonorgestrel implants (Norplant), or oral contraceptives
J Pediatr
(1996) - et al.
Forearm bone density in users of Depo-Provera as a contraceptive method
Fertil Steril
(1999) - et al.
Influence of smoking and oral contraceptives on bone mineral density and bone remodeling in young women: a 2-year study
Contraception
(2003) Compliance with contraceptives and other treatments
Obstet Gynecol
(1996)Risk of contraceptive discontinuation among adolescents
J Adolesc Health Care
(1989)- et al.
Weight change in adolescents who used hormonal contraception
J Adolesc Health
(1999) - et al.
Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate
J Pediatr Adolesc Gynecol
(2002)
Cited by (113)
Eating Disorders in Children and Adolescents: A Practical Review and Update for Pediatric Gynecologists
2021, Journal of Pediatric and Adolescent GynecologyBones and Birth Control in Adolescent Girls
2020, Journal of Pediatric and Adolescent GynecologyBone Mineral Density and Weight Changes in Adolescents Randomized to 3 Doses of Depot Medroxyprogesterone Acetate
2017, Journal of Pediatric and Adolescent GynecologyCanadian Contraception Consensus (part 3 of 4): Chapter 8 - Progestin-only contraception
2016, Journal of Obstetrics and Gynaecology CanadaCanadian Contraception Consensus (Part 3 of 4): Chapter 8 - Progestin-Only Contraception
2016, Journal of Obstetrics and Gynaecology CanadaThe approach to chronic pelvic pain in the adolescent
2014, Obstetrics and Gynecology Clinics of North America
- ☆
Synopsis: Depot medroxyprogesterone acetate administration in adolescent females appears to be associated with a decrease in bone mineral density that persists at 24 months of use.